Article Text
Statistics from Altmetric.com
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Gynaecology ★★★★★★★ Cardiology ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆
METHODS
Design:
2 randomised placebo-controlled trials (Women’s Health Initiative [WHI] trials).
Allocation:
{concealed}*.†
Blinding:
blinded {clinicians, participants, data collectors, outcome assessors, and monitoring committee}*.†
Follow-up period:
mean 5.6‡ and 7.1§ years.
Setting:
40 US clinical centres.
Participants:
27 347 predominantly healthy postmenopausal women 50–79 years of age (mean age 63* and 64|| y).
Intervention
conjugated equine oestrogen (CEO), 0.625 mg/day, plus medroxyprogesterone acetate, 2.5 mg/day (n = 8506), or placebo (n = 8102) in women with an intact uterus; CEO, 0.625 mg/day (n = 5310), or placebo (n = 5429) in women with a hysterectomy.
Outcomes:
coronary heart disease (CHD) (myocardial infarction or CHD death), stroke, total mortality, and a global index.
Participant follow-up:
94%‡|| (intention-to-treat analysis).
MAIN RESULTS
Overall, the HT and placebo groups did not differ for CHD, total mortality, and the global index; the risk of stroke was higher in the HT group …
Footnotes
Linked Articles
- Glossary